FitLife Brands, Inc. (FTLF) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. FitLife Brands, Inc. is a provider of nutritional supplements and wellness products operating under multiple brand portfolios including NDS Nutrition, iSatori, MRC Products, MusclePharm, and the newly acquired Irwin Naturals. The company operates as a single reportable segment.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $23.49M | $15.98M | $55.55M | $49.46M |
| Gross Profit | $8.74M | $7.00M | $22.51M | $21.87M |
| Gross Margin | 37.2% | 43.8% | 40.5% | 44.2% |
| Operating Income | $2.32M | $3.18M | $7.79M | $10.24M |
| Net Income | $0.92M | $2.13M | $4.69M | $6.91M |
| Diluted EPS | $0.09 | $0.21 | $0.47 | $0.70 |
| Cash & Equivalents | $3.51M | $4.47M | - | - |
| Total Debt (Current + Long Term) | $46.46M | $13.05M | - | - |
| Working Capital | $4.38M | $6.83M | - | - |
Material Changes vs. Prior Period
- Acquisition of Irwin Naturals: On August 8, 2025, the company acquired Irwin Naturals for approximately $42.5 million. This transaction drove a 47% revenue increase in Q3 2025 but significantly impacted margins due to lower historical gross margins of the acquired brand and $0.39M in inventory step-up amortization.
- Debt Restructuring: To fund the Irwin acquisition, the company entered a new Credit Agreement with First-Citizens Bank, securing a $40.625M term loan and a $10M revolving line of credit. Total debt increased from $13.05M (Dec 2024) to $46.46M (Sep 2025).
- Revenue Mix Shift: Wholesale revenue share increased to 56% of total revenue in Q3 2025 (from 32% in Q3 2024), while online revenue share decreased to 44% (from 68%), largely due to Irwin's wholesale-heavy sales model.
- Legacy Performance: Legacy FitLife revenue declined 5% in Q3 2025, driven by an 8% drop in online sales for MRC brands (Dr. Tobias) due to reduced Amazon traffic. MusclePharm revenue grew 55% year-over-year, driven by wholesale channel expansion.
Guidance, Outlook, and Risks
- Management Commentary: Management expects continued promotional investment in MusclePharm to drive growth, which may cause margin fluctuations. The company anticipates cash flow from operations and existing credit facilities will be sufficient for liquidity over the next 12 months.
- Debt Covenants: The new Credit Agreement requires maintaining a Senior Funded Debt to EBITDA ratio of no more than 2.75:1.00 (through Q2 2026) and 2.50:1.00 thereafter, and a Fixed Charge Coverage Ratio of at least 1.25:1.00.
- Pro Forma Results: Pro forma net income for the nine months ended Sep 30, 2025, assuming the Irwin acquisition occurred on Jan 1, 2024, would have been $8.39M compared to the reported $4.69M.
- Risks: Key risks include the integration of Irwin Naturals, reliance on GNC (13% of Q3 revenue), and potential goodwill impairment if stock price volatility affects fair value calculations. The company is currently finalizing the purchase price allocation for Irwin.
Investor Verification Checklist
- Debt Service Capacity: Verify the company's ability to meet the new 2.75x Debt/EBITDA covenant given the significant increase in leverage.
- Irwin Integration: Monitor the finalization of the purchase price allocation and the actual performance of Irwin Naturals post-acquisition to assess synergy realization.
- Legacy Brand Trends: Investigate the root causes of the 15% revenue decline in the Dr. Tobias brand and the effectiveness of strategies to recover Amazon traffic.
- Margin Recovery: Track whether gross margins stabilize as the one-time inventory step-up amortization ($0.39M) is fully recognized and promotional spend on MusclePharm yields sustainable returns.